La chaîne d'options affiche les données clés des options sur actions de AZEK Co à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour AZEK Co..

AZEK Co (NYSE:AZEK) Stock, Chaîne d'Options

AZEK Co

The AZEK Co Inc is a designer and manufacturer of beautiful, low maintenance and environmentally sustainable products focused on the fast-growing Outdoor Living market. Its portfolio of products includes decks, rail, trim, outdoor furniture among others. The company operates in two segments: Residential Segment that manufactures and distributes decking, railing, trim, moulding, pergolas and cabanas and accessories through a national network of dealers and distributors and multiple home improvement retailers; and Commercial Segment that manufactures, fabricates and distributes lockers and bathroom partitions. It generates maximum revenue from the Residential segment. The company's brand includes TimberTech; AZEK; Versatex, Ultralox, StruXure, and Intex.

The AZEK Company Inc. Class A Common Stock

The AZEK Co Inc

Bernstein analyst Douglas Harned upgrades Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) from Market Perform to Outperform and raises the price target from $181 to $218.

News

Upgrades

Price Target

Analyst Ratings

Bernstein Upgrades Boeing to Outperform, Raises Price Target to $218

Roper Technologies, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) reported <a href="https://www.benzinga.com/pressreleases/25/04/g45034733/roper-technologies-announces-first-quarter-financial-results" target="_blank" rel="noreferrer noopener">first-quarter results</a> Monday, including quarterly adjusted earnings per share of $4.78, beating <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">the street view of</a> $4.74. Quarterly sales of $1.88 billion outpaced the analyst consensus estimate of $1.82 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/guidance/25/03/44460794/roper-technologies-announces-1-65-billion-centralreach-acquisition-targets-20-growth" rel="noreferrer noopener">Roper Technologies Announces $1.65 Billion CentralReach Acquisition, Targets 20%+ Growth</a>
Revenue increased by 12%, with an 8% contribution from acquisitions and a 5% increase in organic revenue.
The company exited the quarter with cash and equivalents worth $372.8 million and net inventories worth $125.5 million.
Roper Technologies&#8217; long-term debt (net of the current portion) as of quarter end was $6.46 billion, higher than $6.58 billion as of December 31, 2024.
CEO Neil Hunn said that, despite an uncertain macroeconomic backdrop, the company raised its full-year outlook, underpinned by demand for its mission-critical solutions and expansion of its recurring revenue base. Additionally, it is well-positioned to continue executing its capital deployment strategy, fueled by its significant M&amp;A firepower and a large pipeline of acquisition opportunities.
Outlook:&nbsp;Roper Technologies expects fiscal 2025 adjusted earnings per share of $19.80-$20.05 (compared to a previous outlook of $19.75-$20.00),&nbsp;versus the $19.92 estimate. It increased its full-year total revenue growth outlook to ~12% or $7.88 billion (compared to a previous outlook of 10%+ or $7.74 billion) and an analyst estimate of $7.74 billion. It reiterated organic revenue growth of +6-7%.
The company anticipates adjusted EPS of $4.80- $4.84 for the second quarter, compared to <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">the $4.86 estimate</a>.
Price Action: ROP stock is down 0.49% to $554.95 in the premarket at last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44852860/nvidia-lam-research-and-marvell-to-face-least-impact-from-tariffs-while-intel-and-arm-could-suffer-more-bofa-analyst" target="_blank" rel="noreferrer noopener">These Semiconductor Stocks To Face Least Tariffs Impact Compared To Intel</a></li>
</ul>
Photo: Shutterstock

Earnings

Guidance

Roper Lifts 2025 Guidance After Solid Q1, CEO Sees Growth Ahead Despite Economic Uncertainty

Macro Economic Events

Econ #s

Economics

Dallas Fed Mfg Business Index For April -35.8 Vs -16.3 Prior

Equitable Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQH#NYSE">EQH</a>) has outperformed the market over the past 5 years by 9.62% on an annualized basis producing an average annual return of 23.88%. Currently, Equitable Holdings has a market capitalization of $15.58 billion. 
Buying $1000 In EQH: If an investor had bought $1000 of EQH stock 5 years ago, it would be worth $2,761.74 today based on a price of $50.63 for EQH at the time of writing.
<h3>Equitable Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745850615_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

U.S. stocks were mostly higher, with the Dow Jones index gaining around 200 points on Monday.
Shares of CEMEX, S.A.B. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CX#NYSE">CX</a>) rose sharply during Monday's session following <a href="https://www.benzinga.com/25/04/45038161/cemexs-q1-results-show-strong-emea-growth-offset-by-mexican-market-struggles">first-quarter results</a>.
The company reported first-quarter net sales of $3.65 million, missing the consensus of $3.80 billion. Net sales fell 7% year over year (Y/Y), mainly due to lower volumes in Mexico. EBITDA declined 18% Y/Y to $601 million in the quarter, with a margin contracted 2.0ppt Y/Y to 16.5% in the quarter.
Cemex expects recurrent yearly EBITDA savings of at least $150 million in 2025 and $350 million by 2027.
Cemex shares jumped 4.2% to $6.16 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Plug Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) shares jumped 39.4% to $1.13 after the company signed a secured credit facility with Yorkville Advisors. The company also reported preliminary first-quarter results.</li>
<li>CG Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) surged 30% to $29.02 after the company announced that cretostimogene grenadenorepvec monotherapy data was presented at the American Urological Association Annual Meeting.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) rose 24.5% to $4.07.</li>
<li>Sabre Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABR#NASDAQ">SABR</a>) gained 20.3% to $2.6350 as the company entered into definitive agreement to sell its Hospitality Solutions business unit to TPG for $1.1 billion.</li>
<li>Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) rose 17.4% to $8.23.</li>
<li>TMC the metals company Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) gained 15.9% to $3.5350.</li>
<li>Rapport Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPP#NASDAQ">RAPP</a>) climbed 12.6% to $11.96.</li>
<li>VEON Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>) gained 12.2% to $47.83.</li>
<li>ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) rose 12% to $24.49 as the company announced the FDA approval of its yield enhancement production process.</li>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) gained 10% to $25.79.</li>
<li>UroGen Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) gained 10% to $10.85 after the company highlighted nearly four-year duration of response in OLYMPUS long-term follow-up study of JELMYTO.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) rose 7.6% to $7.41.</li>
<li>Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) gained 6.1% to $29.82.</li>
<li>Peloton Interactive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) rose 5.4% to $6.63. Truist Securities analyst Youssef Squali upgraded Peloton Interactive from Hold to Buy.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45038052/top-2-industrials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Industrials Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

Markets

Movers

ADMA

CGON

Hims & Hers Health, Inc. Class A Common Stock

HIMS

PLUG

PONY

PTON

RAPP

SABR

SMMT

URGN

VEON

WOLF

Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday

Biohaven Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) shares are trading higher premarket on Monday after the company disclosed that it has entered into an agreement with Oberland Capital Management LLC<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n45035764/biohaven-announces-investment-up-to-600-million-by-oberland-capital" rel="noreferrer noopener"> to invest up to $600 million</a>.
The investment is structured through a non-dilutive Note Purchase Agreement (NPA). The first tranche of $250 million in gross proceeds is expected to be funded at closing on or before April 30, 2025.
Following FDA approval of troriluzole, Biohaven may draw an additional $150 million at its option, while another $200 million could be made available upon mutual agreement for strategic acquisitions and related expenses, subject to specific conditions.
Also Read: <a href="https://www.benzinga.com/25/03/44087186/strong-igg-reduction-data-positions-biohavens-bhv-1300-as-potential-autoimmune-therapy" target="_blank" rel="noreferrer noopener">Strong Immunoglobulin Reduction Data Positions Biohaven&#8217;s BHV-1300 As Potential Autoimmune Therapy</a>
The NPA also grants Oberland a right to regulatory milestone payments through 2030 and tiered single-digit royalties on global net sales of troriluzole for up to 10 years, capped at a predetermined multiple of the invested amount.
The additional funding is expected to bolster Biohaven's clinical trial programs across its development portfolio and support commercialization initiatives ahead of a potential U.S. FDA approval of troriluzole for spinocerebellar ataxia (SCA), a group of rare, progressively debilitating, and fatal genetic disorders currently lacking approved treatments.
As of Dec. 31, cash, cash equivalents, marketable securities and restricted <a href="https://www.benzinga.com/pressreleases/25/03/n44074016/biohaven-reports-recent-business-developments-and-fourth-quarter-and-full-year-2024-financial-resu" target="_blank" rel="noreferrer noopener">cash stood at around $489 million</a>.
Investors can gain exposure to the stock via Simplify Health Care ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINK#NYSE">PINK</a>) and iShares Trust iShares Neuroscience and Healthcare ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBRN#NYSE">IBRN</a>).
Price Action: Biohaven shares are up 5.85% at $21.00 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/44401719" target="_blank" rel="noreferrer noopener">Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data</a></li>
</ul>

Equities

Mid Cap

Financing

BHVN

iShares Trust iShares Neuroscience and Healthcare ETF

IBRN

PINK

Biohaven Rallies On Heels Of $600M Funding Agreement With Oberland

WIIM

Sabre shares are trading higher after the company announced that TPG agreed to acquire Sabre's Hospitality Solutions business.

XRTX

XRTX stock has given up its prior gain. XORTX Therapeutics shares were trading higher after the comapny announced that the patent "Xanthine Oxidase Inhibitor Formulations" will be granted by the European Patent Office.

JMP Securities analyst David Scharf reiterates Bread Finl Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFH#NYSE">BFH</a>) from Market Perform to Market Perform.

Reiteration

JMP Securities Reiterates Market Perform on Bread Finl Hldgsto Market Perform

Wells Fargo analyst Joe Quatrochi maintains ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with a Overweight and lowers the price target from $185 to $150.

Wells Fargo Maintains Overweight on ARM Holdings, Lowers Price Target to $150

Marriott International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) announced plans on Monday to <a href="https://www.benzinga.com/pressreleases/25/04/n45035022/marriott-international-to-acquire-the-citizenm-brand">buy the lifestyle hotel brand</a> CitizenM.
The acquisition is expected to help Marriott expand offerings for its guests and Marriott Bonvoy loyalty members across global markets. CitizenM has 36 hotels operating in over 20 cities worldwide, including in New York, London, Paris and Rome.
CitizenM also has three additional hotels under construction, slated for completion by mid-2026. Long-term expansion is planned across Marriott's global regions.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44800444/goldman-sachs-cuts-outlook-for-these-hotel-and-lodging-stocks-as-potential-recession-looms">Goldman Sachs Cuts Outlook For These Hotel And Lodging Stocks As Potential Recession Looms</a>
Under the terms of the deal, Marriott will pay $355 million for CitizenM and its related intellectual property. The CitizenM properties currently owned and leased by the seller will shift to new long-term franchise agreements managed by Marriott.
&#8220;As we continue to drive best-in-class experiences for travelers, today&#8217;s announcement builds upon Marriott&#8217;s commitment to enhance options for guests and Marriott Bonvoy members,&#8221; said&nbsp;Marriott president and CEO, Anthony Capuano.
&#8220;Marriott has a proven track record of growing acquired brands significantly by leveraging our global development ecosystem, the benefits of our industry-leading affiliation cost structure, and the power of our award-winning Marriott Bonvoy loyalty platform.&#8221;
Marriott <a href="https://www.benzinga.com/news/earnings/25/02/43629316/marriott-tops-q4-estimates-as-2025-outlook-pressures-stock">held $400 million in cash and equivalents</a> as of Dec. 31, 2024.
Future growth incentives could see the seller earn up to an additional $110 million, based on brand expansion achievements over a multi-year timeframe, starting in the fourth year after closing. 
CitizenM, established in 2008, is known for its tech-driven hospitality, artistic design, and smart use of space, offering travelers modern rooms, and rooftop terraces at an affordable price.
Pending regulatory approvals, the acquisition is expected to close in 2025. Marriott projects that this move will help drive its net room growth to nearly 5% for the full year 2025.
Price Action: MAR shares traded higher by 1.75% at $240.34 at last check Monday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/25/04/45011035/meta-booz-allen-launch-space-llama-ai-system-for-space-station-operations">Meta, Booz Allen Launch &#8216;Space Llama&#8217; AI System For Space Station Operations</a></li>
</ul>
Image: Shutterstock

General

Marriott Bets $355M On Trendy CitizenM Hotels To Woo Modern Travelers

Wells Fargo analyst Steven Cahall maintains Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Overweight and lowers the price target from $129 to $93.

ROKU

Wells Fargo Maintains Overweight on Roku, Lowers Price Target to $93

JMP Securities analyst Constantine Davides reiterates Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) from Market Perform to Market Perform.

JMP Securities Reiterates Market Perform on Agilon Healthto Market Perform

Wells Fargo analyst Steven Cahall maintains Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) with a Equal-Weight and raises the price target from $380 to $400.

CHTR

Wells Fargo Maintains Equal-Weight on Charter Communications, Raises Price Target to $400

Wells Fargo analyst Christian Wetherbee maintains Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) with a Equal-Weight and lowers the price target from $400 to $260.

SAIA

Wells Fargo Maintains Equal-Weight on Saia, Lowers Price Target to $260

Wells Fargo analyst Matthew Akers maintains CACI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CACI#NYSE">CACI</a>) with a Overweight and raises the price target from $438 to $513.

CACI

Wells Fargo Maintains Overweight on CACI International, Raises Price Target to $513

Cantor Fitzgerald analyst Josh Schimmer reiterates CG Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) with a Overweight and maintains $75 price target.

Cantor Fitzgerald Reiterates Overweight on CG Oncology, Maintains $75 Price Target

Wells Fargo analyst Finian O'Shea maintains TriplePoint Venture Gwth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPVG#NYSE">TPVG</a>) with a Underweight and lowers the price target from $6.5 to $5.5.

TPVG

Wells Fargo Maintains Underweight on TriplePoint Venture Gwth, Lowers Price Target to $5.5

Wells Fargo analyst Finian O'Shea maintains Trinity Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIN#NASDAQ">TRIN</a>) with a Underweight and lowers the price target from $14 to $13.

TRIN

Wells Fargo Maintains Underweight on Trinity Cap, Lowers Price Target to $13

Wells Fargo analyst Finian O'Shea maintains Sixth Street Specialty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSLX#NYSE">TSLX</a>) with a Overweight and lowers the price target from $23 to $22.

TSLX

Wells Fargo Maintains Overweight on Sixth Street Specialty, Lowers Price Target to $22

Press Releases

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of The AZEK Company Inc. - AZEK

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AZEK, LNSR, DNB on Behalf of Shareholders

Legal

AZEK Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of The AZEK Company to James Hardie Industries

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of The AZEK Company Inc.

AZEK INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AZEK Company Inc. - AZEK

Comments

AZEK Co

AZEK Co (AZEK) Options

AZEK Co (NYSE:AZEK) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL